TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

You Are Here: Home  »  Disorders A - Z  »  NINDS Clinical Trials  » 

Skip secondary menu

PRX-00023 Therapy in Localization-Related Epilepsy

See All Epilepsy Trials

The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, is looking for individuals to participate in clinical studies. Participating in clinical trials allows you to play an active role in research on the nature and causes of many disorders of the brain and nervous system, and to possibly help physician-scientists develop future treatments. The information below is designed to help you quickly learn about actively recruiting research studies for which you or someone you know may be eligible.


The purpose of this study (11-N-0039) is to find out if an experimental drug called PRX-00023 reduces the frequency of seizures in people with localization-related epilepsy.  Localization-related epilepsy is a type of epilepsy that starts in only one part of the brain.

The brain chemical serotonin helps nerve cells communicate.  Previous research suggests that serotonin activity may be lower in brain areas where seizures start.  Increasing activity at the receptor site on nerve cells that bind serotonin may help prevent seizures.  In the study, researchers will use PRX-00023—which attaches to serotonin receptors and increases serotonin activity—to test if the drug can reduce seizure frequency in people whose seizures are not well-controlled with anti-seizure medication.

Thirty people with localization-related epilepsy will participate in this study.  The study is comprised of six phases, and requires 9 visits to the NIH Clinical Center in Bethesda, MD—over an approximately 34-week period. All study visits will take place at the NIH Clinical Center.

In phase 1, volunteers will be screened to determine eligibility.  Screening will include information collected from protocol 01-N-0139, a routine screening protocol, as well as medical history, a physical examination, an electroencephalogram (EEG), and blood and urine testing.

In phase 2, researchers will observe and evaluate how frequently participants’ seizures occur before they begin the study medication.  Participants will have mood, learning, and memory tests, and a PET scan, and be given a calendar to track seizures for 6 weeks.  Some participants may also have an EEG and be asked to provide a saliva sample for genetic testing.

In phase 3—the first study medication phase—each participant will receive either the study medication (PRX-00023) or a placebo (inactive medication) for 12 weeks.  Participants will keep a calendar to track their seizures, response to the medication, and any side effects.  During the study visit, participants will have a physical examination, blood test, and an electrocardiogram (ECG).

At the phase 4 interim period, participants will have a study visit which will include an ECG and neuropsychological and mood rating tests.  Researchers will gradually decrease the study medication dosage over a 10-day period and then stop the medication completely.  Participants will then go through a washout period in which they will stay off of the study medication for 2-3 weeks.

In phase 5, participants will begin the second study medication phase for another 12-week period.  If participants received study medication during phase 3, they will receive placebo during phase 5.  If participants received placebo during phase 3, then they will receive study medication during phase 5.

In phase 6, one month after study medication has stopped, participants will return to the NIH Clinical Center for follow-up evaluation which will include a physical exam, ECG, blood, urine tests, and mood tests.

Eligibility Criteria:

Please follow this link for trial eligibility information to share with your doctor.

Study Design: 


Study Locations: 

Bethesda, Maryland

For more information:

Contact: Tamika Mason, Tel: 301-496-1923, Email:; or Irene Dustin, Tel: 301-451-9284, Email:; or visit:

Last Reviewed July 21, 2016